FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885698198> ?p ?o ?g. }

• W2885698198 endingPage "263" @default.
• W2885698198 startingPage "LB" @default.
• W2885698198 abstract "Abstract Bruton tyrosine kinase (BTK) is an essential kinase in the B-cell receptor (BCR) signalling pathway. Acalabrutinib is a potent and highly selective irreversible BTK inhibitor that received accelerated approval by FDA for the treatment of Relapsed/Refractory Mantle Cell Lymphoma. It is proposed to be combined with the Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor AZD6738, in a Phase I/II proof of concept clinical trial to assess safety and efficacy in patients with B-cell malignancies. ATR is a key regulator of DNA replication, repair and cell cycle checkpoints. The Activated B-Cell (ABC) subtype of Diffuse Large B-Cell Lymphoma (DLBCL) is associated with chronic active BCR signalling, and given our previous identification of sensitivity to AZD6738 in ABC-DLBCL cell lines, we hypothesised that combination with acalabrutinib may have additional therapeutic benefit. Here we report preliminary data to support combination efficacy in models of ABC-type DLBCL. The growth inhibitory and cell kill effect of AZD6738 and acalabrutinib in combination was assessed in 3 ABC and 4 GCB DLBCL cell lines. Combination activity and cell kill was detected specifically in the ABC-type TMD8 cell line. Using flow cytometry, we show that the cell kill effects of the drug combination were dependent on dose and schedule. Single agent treatment with 5 nM acalabrutinib or 0.5 µM AZD6738 for 72 h, caused cell death in 12% and 17% of cells respectively. The equivalent doses given in combination for 72 h induced cell death in 39% of cells, indicative of a greater than additive effect. Cell killing was increased with longer co-exposure to the combination, shown by an increase in cell death from 18% at 24 h, to 30% at 48 h. Acalabrutinib is dosed on a BID schedule, thus we tested whether its activity in combination with AZD6738 was affected by pre- or post-addition of acalabrutinib. A 24 h pre-treatment of cells with acalabrutinib, followed by the combination of AZD6738 and acalabrutinib for 48 h resulted in 20% cell death, whereas 48 h combination treatment followed by 24 h acalabrutinib monotherapy caused a similar 27% increase in death, suggesting that combination efficacy is not dependent on sequence of drug administration. Furthermore, the mRNA expression of BTK target genes in ABC-DLBCL cell lines was modulated by acalabrutinib, however there was no additional modulation to this pathway by the combination with AZD6738, suggesting the two agents kill cells through different mechanisms of action. In the TMD8 xenograft mouse model, daily dosing of AZD6738 (25 mg/kg) with twice daily dosing of acalabrutinib (20 mg/kg) was well tolerated and resulted in complete and durable tumor regressions (8/8 tumors), whereas single agent treatments resulted in tumor growth delay. Collectively, our preliminary data support a rationale for combining BTK and ATR inhibitors for an effective and alternative treatment option in ABC-DLBCL. Citation Format: Lucy A. Young, Oona Delpuech, Brandon Willis, Alexandra Bussey, Zena Wilson, Michelle Dupont, Carlos Grajales, Andrew Bloecher, Todd Covey, Kate Wills, Alan Lau, Simon J. Hollingsworth. Preclinical efficacy of the ATR inhibitor AZD6738 in combination with the BTK inhibitor acalabrutinib in ABC-DLBCL models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-263." @default.
• W2885698198 created "2018-08-22" @default.
• W2885698198 creator A5004904827 @default.
• W2885698198 creator A5007951802 @default.
• W2885698198 creator A5019973961 @default.
• W2885698198 creator A5021226799 @default.
• W2885698198 creator A5022038312 @default.
• W2885698198 creator A5036427433 @default.
• W2885698198 creator A5051654875 @default.
• W2885698198 creator A5055277039 @default.
• W2885698198 creator A5069830252 @default.
• W2885698198 creator A5079476437 @default.
• W2885698198 creator A5081596117 @default.
• W2885698198 creator A5089494931 @default.
• W2885698198 date "2018-07-01" @default.
• W2885698198 modified "2023-10-16" @default.
• W2885698198 title "Abstract LB-263: Preclinical efficacy of the ATR inhibitor AZD6738 in combination with the BTK inhibitor acalabrutinib in ABC-DLBCL models" @default.
• W2885698198 doi "https://doi.org/10.1158/1538-7445.am2018-lb-263" @default.
• W2885698198 hasPublicationYear "2018" @default.
• W2885698198 type Work @default.
• W2885698198 sameAs 2885698198 @default.
• W2885698198 citedByCount "3" @default.
• W2885698198 countsByYear W28856981982020 @default.
• W2885698198 countsByYear W28856981982023 @default.
• W2885698198 crossrefType "journal-article" @default.
• W2885698198 hasAuthorship W2885698198A5004904827 @default.
• W2885698198 hasAuthorship W2885698198A5007951802 @default.
• W2885698198 hasAuthorship W2885698198A5019973961 @default.
• W2885698198 hasAuthorship W2885698198A5021226799 @default.
• W2885698198 hasAuthorship W2885698198A5022038312 @default.
• W2885698198 hasAuthorship W2885698198A5036427433 @default.
• W2885698198 hasAuthorship W2885698198A5051654875 @default.
• W2885698198 hasAuthorship W2885698198A5055277039 @default.
• W2885698198 hasAuthorship W2885698198A5069830252 @default.
• W2885698198 hasAuthorship W2885698198A5079476437 @default.
• W2885698198 hasAuthorship W2885698198A5081596117 @default.
• W2885698198 hasAuthorship W2885698198A5089494931 @default.
• W2885698198 hasConcept C126322002 @default.
• W2885698198 hasConcept C170493617 @default.
• W2885698198 hasConcept C203014093 @default.
• W2885698198 hasConcept C2777525834 @default.
• W2885698198 hasConcept C2777938653 @default.
• W2885698198 hasConcept C2778461978 @default.
• W2885698198 hasConcept C2778559949 @default.
• W2885698198 hasConcept C2779338263 @default.
• W2885698198 hasConcept C2779878957 @default.
• W2885698198 hasConcept C42362537 @default.
• W2885698198 hasConcept C502942594 @default.
• W2885698198 hasConcept C71924100 @default.
• W2885698198 hasConcept C90059517 @default.
• W2885698198 hasConcept C98274493 @default.
• W2885698198 hasConceptScore W2885698198C126322002 @default.
• W2885698198 hasConceptScore W2885698198C170493617 @default.
• W2885698198 hasConceptScore W2885698198C203014093 @default.
• W2885698198 hasConceptScore W2885698198C2777525834 @default.
• W2885698198 hasConceptScore W2885698198C2777938653 @default.
• W2885698198 hasConceptScore W2885698198C2778461978 @default.
• W2885698198 hasConceptScore W2885698198C2778559949 @default.
• W2885698198 hasConceptScore W2885698198C2779338263 @default.
• W2885698198 hasConceptScore W2885698198C2779878957 @default.
• W2885698198 hasConceptScore W2885698198C42362537 @default.
• W2885698198 hasConceptScore W2885698198C502942594 @default.
• W2885698198 hasConceptScore W2885698198C71924100 @default.
• W2885698198 hasConceptScore W2885698198C90059517 @default.
• W2885698198 hasConceptScore W2885698198C98274493 @default.
• W2885698198 hasIssue "13_Supplement" @default.
• W2885698198 hasLocation W28856981981 @default.
• W2885698198 hasOpenAccess W2885698198 @default.
• W2885698198 hasPrimaryLocation W28856981981 @default.
• W2885698198 hasRelatedWork W1780111622 @default.
• W2885698198 hasRelatedWork W265268219 @default.
• W2885698198 hasRelatedWork W2741571497 @default.
• W2885698198 hasRelatedWork W2979571657 @default.
• W2885698198 hasRelatedWork W2986757832 @default.
• W2885698198 hasRelatedWork W4362593813 @default.
• W2885698198 hasRelatedWork W4362596157 @default.
• W2885698198 hasRelatedWork W4375865384 @default.
• W2885698198 hasRelatedWork W4375865410 @default.
• W2885698198 hasRelatedWork W2475047365 @default.
• W2885698198 hasVolume "78" @default.
• W2885698198 isParatext "false" @default.
• W2885698198 isRetracted "false" @default.
• W2885698198 magId "2885698198" @default.
• W2885698198 workType "article" @default.